All data are based on the daily closing price as of November 13, 2026
t

Tanvex BioPharma

6541.TW
0.86 USD
0.01
+1.18%

Overview

Last close
0.86 usd
Market cap
226.61M usd
52 week high
2.12 usd
52 week low
0.82 usd
Target price
1.59 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
11.3242
Price/Book Value
1.4996
Enterprise Value
271.81M usd
EV/Revenue
13.5915
EV/EBITDA
-9.0582

Key financials

Revenue TTM
20.00M usd
Gross Profit TTM
-27.33M usd
EBITDA TTM
-39.48M usd
Earnings per Share
-0.17 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
  • Symbol
    6541.TW
  • Exchange
    TW
  • Isin
    KYG8676P1037
  • Country
    Cayman Islands
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    George Town
  • Web site
    https://www.tanvex.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top